Fig. 8.

Therapeutic effect of ALZ003 on the growth of TMZ-resistant glioblastoma in vivo. A. After intracranial transplantation with TMZ-resistant U87MG cells for 10 days, mice were orally and intravenously administrated with TMZ (15 mg/kg) and ALZ003 three times per week, respectively. The date of death was recorded and analyzed by Log-Rank Test. (**p = 0.0052). B. The mouse brains were paraffin embedded and subject to slides preparation followed by hematoxylin- and eosin-staining. Tumor in each slide was indicated. The scale bar for HE staining of whole brain slice is 1 mm, and that for other IHC images is 0.5 mm. C. The area of tumor was quantitated by the Image J software. The difference with the control group was analyzed using Student's t-test (*p < 0.05). D. The alteration in body weight of transplanted mice during the process of experiment. The difference with DMSO group was analyzed using two-way ANOVA. P-value was indicated. E, F. The slides were immunostained using the antibody targeting AR, c-myc, Ki-67 or PCNA. The scale bar represents 0.5 mm. F. The intensity of the interested protein was quantified using Score definition. The comparison was performed using Student's t-test. P-value was indicated.